Pipeline

                        Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

                        Pipeline

                        HIV / AIDS

                        Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        • Emtricitabine and tenofovir alafenamide

                          Potential Indication: PrEP

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-6207 (Capsid Inhibitor)

                          Potential Indication: HIV/AIDS

                          Phase 1
                          Phase 2
                          Phase 3
                        • Vesatolimod (TLR-7 agonist)

                          Potential Indication: HIV/AIDS

                          Phase 1
                          Phase 2
                          Phase 3
                        • Elipovimab (bNab)

                          Potential Indication: HIV/AIDS

                          Phase 1
                          Phase 2
                          Phase 3

                        Liver Diseases

                        Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        • Cilofexor (FXR agonist)

                          Potential Indication: NASH

                          Phase 1
                          Phase 2
                          Phase 3
                        • Cilofexor (FXR agonist)

                          Potential Indication: Primary Biliary Cirrhosis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Cilofexor (FXR agonist)

                          Potential Indication: Primary Sclerosing Cholangitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Firsocostat (ACC Inhibitor)

                          Potential Indication: NASH

                          Phase 1
                          Phase 2
                          Phase 3
                        • Selgantolimod (TLR-8 agonist)

                          Potential Indication: HBV

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-4224 (PD-L1 Inhibitor)

                          Potential Indication: HBV

                          Phase 1
                          Phase 2
                          Phase 3

                        Hematology / Oncology

                        Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        • Axicabtagene ciloleucel

                          Trial: ZUMA-5 Potential Indication: Indolent NHL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axicabtagene ciloleucel

                          Trial: ZUMA-6 Potential Indication: DLBCL (+PD-L1 mAb)

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axicabtagene ciloleucel

                          Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axicabtagene ciloleucel

                          Trial: ZUMA-11, Potential Indication: DLBCL (+4-1BB)

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axicabtagene ciloeucel

                          Trial: ZUMA-12 Potential Indication: 1st line DLBCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axicabtagene ciloleucel

                          Trial: ZUMA-14 Potential Indication: DLBCL (+rituximab or lenalidomide)

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Trial: ZUMA-2 Potential Indication: MCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Trial: ZUMA-3 Potential Indication: Adult ALL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Trial: ZUMA-4 Potential Indication: Pediatric ALL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Trial: ZUMA-8 Potential Indication: CLL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KITE-718 (MAGE A3/A6)

                          Potential Indication: Solid Tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • KITE-439 (HPV E7)

                          Potential Indication: Solid Tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-1423 (bi-specific antibody)

                          Potential Indication: Solid Tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-4224 (oral PD-L1 inhibitor)

                          Potential Indication: Solid Tumor

                          Phase 1
                          Phase 2
                          Phase 3

                        Inflammation / Respiratory

                        Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        • Filgotinib (JAK1 inhibitor)

                          Potential Indication: Rheumatoid Arthritis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (JAK1 inhibitor)

                          Potential Indication: Crohn's Disease

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (JAK1 inhibitor)

                          Potential Indication: Ulcerative Colitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (JAK-1 inhibitor)

                          Potential Indication: Psoriatic Arthritis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (JAK1 inhibitor)

                          Potential Indication: Inflammatory Diseases

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (JAK-1 inhibitor)

                          Potential Indication: Ankylosing Spondylitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-9876 (Syk inhibitor)

                          Potential Indication: Sjogren’s Syndrome

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-9876 (Syk inhibitor)

                          Potential Indication: Lupus

                          Phase 1
                          Phase 2
                          Phase 3
                        • GS-4875 (TPL2 inhibitor)

                          Potential Indication: Ulcerative Colitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-1690

                          Potential Indication: Idiopathic Pulmonary Fibrosis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-1690

                          Potential Indication: Systemic Sclerosis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Selonsertib (ASK-1 inhibitor)

                          Potential Indication: DKD

                          Phase 1
                          Phase 2
                          Phase 3

                        Other

                        Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        • Remdesivir (GS-5734, Nuc inhibitor)

                          Potential Indication: Ebola Virus Infection

                          Phase 1
                          Phase 2
                          Phase 3

                        Some of the content on this page is not intended for users outside the US.

                        手机看片1024